Onartuzumab
- CAS No.
- 1133766-06-9
- Chemical Name:
- Onartuzumab
- Synonyms
- Onartuzumab;Onartuzumab (anti-MET);Research Grade Onartuzumab;RG-3638|||PRO-14396|||MetMAb;Research Grade Onartuzumab (DHC34202)
- CBNumber:
- CB28080831
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
- MSDS File:
- SDS
| Product description | Number | Pack Size | Price |
| Onartuzumab 99.62% | CS-0612544 | 1mg | $320 |
| Onartuzumab 99.62% | CS-0612544 | 5mg | $1029 |
| Onartuzumab 99.62% | CS-0612544 | 10mg | $1625 |
| Onartuzumab 99.62% | CS-0612544 | 25mg | $3142 |
| Onartuzumab | AA0294SF | 1mg | $215 |
| form | Liquid |
|---|---|
| color | Colorless to light yellow |
| FDA UNII | MS1J9720WC |
| NCI Drug Dictionary | onartuzumab |
Onartuzumab price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0612544 | Onartuzumab 99.62% | 1133766-06-9 | 1mg | $320 | 2026-06-04 | Buy |
| ChemScene | CS-0612544 | Onartuzumab 99.62% | 1133766-06-9 | 5mg | $1029 | 2026-06-04 | Buy |
| ChemScene | CS-0612544 | Onartuzumab 99.62% | 1133766-06-9 | 10mg | $1625 | 2026-06-04 | Buy |
| ChemScene | CS-0612544 | Onartuzumab 99.62% | 1133766-06-9 | 25mg | $3142 | 2026-06-04 | Buy |
| aablocks | AA0294SF | Onartuzumab | 1133766-06-9 | 1mg | $215 | 2026-06-02 | Buy |
Onartuzumab Chemical Properties,Uses,Production
Description
Onartuzumab is a monoclonal antibody that blocks the binding of HGF to the MET receptor.
Uses
Onartuzumab (MetMAb) is a unique, humanized and affinity-matured monovalent (one-armed) monoclonal antibody against the MET receptor. Onartuzumab potently inhibits HGF binding and receptor phosphorylation and signaling. Onartuzumab has antibody-like pharmacokinetics and antitumor activity[1].
Clinical Use
Onartuzumab is ineffective in improving clinical outcomes in (i) combination with current first-line chemotherapy in advanced nonsquamous cell NSCLC , (ii) combination with erlotinib in previously treated stage IIIB or IV NSCLC patients (Phase III) , and (iii) combination with platinum-doublet chemotherapy in advanced squamous cell NSCLC (Phase II) .
in vivo
Onartuzumab (30 mg/kg, IP, twice a week for 2 mouth) suppresses tumor growth[3].
| Animal Model: | Human HGF-transgenic SCID mice implanted with BxPC3 tumor cells, nude (nu/nu) mice implanted with KP4 human pancreatic xenograft tumor cells[3] |
| Dosage: | 30 mg/kg |
| Administration: | IP, twice a week for 2 mouth |
| Result: | Suppressed tumor growth, but did not affect the mean in vivo human HGF levels. |
| Animal Model: | U-87 MG tumor-bearing mice[3] |
| Dosage: | 30 mg/kg |
| Administration: | IP, once |
| Result: | Resulted in profound TGI (tumor growth inhibition) with 4/10 mice demonstrating a partial response (>50% reduction in tumor size) and 6/10 mice demonstrating a complete response (100% tumor regression). |
References
[1] Merchant M, et al. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):E2987-96. DOI:10.1073/pnas.1302725110
[2] Prell RA, et al. Placental and Fetal Effects of Onartuzumab, a Met/HGF Signaling Antagonist, When Administered to Pregnant Cynomolgus Monkeys. Toxicol Sci. 2018 Sep 1;165(1):186-197. DOI:10.1093/toxsci/kfy141
Onartuzumab Preparation Products And Raw materials
Raw materials
Preparation Products
Onartuzumab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| TargetMol Chemicals Inc. | +1-781-999-5354; +1-00000000000 | marketing@targetmol.com | United States | 32431 | 58 |
| Aladdin Scientific | tp@aladdinsci.com | United States | 54746 | 58 | |
| BOC Sciences | 1-631-485-4226; 16314854226 | info@bocsci.com | United States | 9920 | 65 |
| Shanghai YuanYe Biotechnology Co., Ltd. | 13636370518 | shyysw007@163.com | China | 89667 | 60 |
| ShangHai Biochempartner Co.,Ltd | 177-54423994 17754423994 | 2853530910@QQ.com | China | 7999 | 62 |
| Wuhan Chemstan Biotechnology Co., Ltd. | 027-65317797 15926423062 | 422450190@qq.com | China | 10307 | 58 |
| Beijing Jin Ming Biotechnology Co., Ltd. | 010-60605840 | psaitong@jm-bio.com | China | 27066 | 58 |
| TargetMol Chemicals Inc. | 4008200310 15002144251 | marketing@tsbiochem.com | China | 24951 | 58 |
| Biolab Reagents | 027-65279366 18108604356 | products@biolabreagent.com | China | 9864 | 58 |
| Wuhan Jingkangen Biomedical Technology Co., Ltd | 13720134139 086-15871494362 13720134139 | orders@jknbiochem.com | China | 7238 | 58 |
View Lastest Price from Onartuzumab manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2026-07-27 | Onartuzumab
1133766-06-9
|
$243.00-1230.00 | 97.6% (SEC-HPLC) | 10g | TargetMol Chemicals Inc. |
-
- Onartuzumab
1133766-06-9
- $243.00-1230.00
- 97.6% (SEC-HPLC)
- TargetMol Chemicals Inc.
